REMEGEN (09995) surged nearly 5% in early trading. As of press time, the stock was up 4.75% to HK$93.75, with a trading volume of HK$226 million.

On the news front, REMEGEN announced that its self-developed innovative drug telitacicept (trade name: Taiping), the world's first BLyS/APRIL dual-target fusion protein, for treating primary immunoglobulin A (IgA) nephropathy, has received acceptance from the Center for Drug Evaluation (CDE) of the National Medical Products Administration and has been included in the priority review process. Telitacicept has become the first domestically developed original new drug to apply for market approval in the IgA nephropathy field.

Additionally, on September 23, VorBio, telitacicept's overseas partner, announced the appointment of Dr. Navid Z. Khan as Chief Medical Officer. Prior to joining, Dr. Khan had led the global development of innovative drugs including efgartigimod and has deep experience in neurology and autoimmune fields.

Huatai Securities noted that telitacicept demonstrates strong global competitiveness, with best-in-class potential for treating myasthenia gravis (MG), and represents the world's first innovative drug to report for production in the primary Sjögren's syndrome (pSS) field. Combined with Dr. Khan's extensive experience, the firm is optimistic about telitacicept's global development prospects and maintains a "Buy" rating for both A-shares and H-shares.